ADPT — Adaptogenics Health Income Statement
0.000.00%
Last trade - 00:00- CA$0.33m
- CA$0.26m
- CA$0.00m
Annual income statement for Adaptogenics Health, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 0 | 0 | 0.001 | 0 |
| Cost of Revenue | ||||
| Gross Profit | — | — | 0 | -0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Total Operating Expenses | 0.141 | 0.271 | 0.115 | 0.08 |
| Operating Profit | -0.141 | -0.271 | -0.114 | -0.08 |
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.141 | -0.266 | -0.147 | -0.075 |
| Net Income After Taxes | -0.141 | -0.266 | -0.147 | -0.075 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.141 | -0.266 | -0.147 | -0.075 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.141 | -0.266 | -0.147 | -0.075 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.009 | -0.016 | -0.009 | -0.005 |
| Dividends per Share |